AKTS
AKTS
NASDAQ · Biotechnology

Aktis Oncology Inc

$18.98
-0.59 (-3.01%)
As of Feb 8, 1:43 PM ET ·
Income Statement
FY 2026 FY 2025 FY 2025 FY 2024 FY 2023
Revenue 14.6K 9.1K 130.17M 117.17M 104.10M
Net Income -89,830 -50,362 -10,475,587 -10,038,830 -10,712,566
EPS
Profit Margin -613.3% -582.6% -8.1% -8.6% -10.3%
Rev Growth +60.5% +60.5% -3.3% +1.7% -5.4%
Balance Sheet
FY 2026 FY 2025 FY 2025 FY 2024 FY 2023
Total Debt 152.8K 152.8K 61.47M 57.51M 59.72M
Total Equity 299.4K 299.4K 829.17M 766.73M 731.61M
D/E Ratio 0.51 0.51 0.07 0.08 0.08
Cash Flow
FY 2026 FY 2025 FY 2025 FY 2024 FY 2023
EBITDA -82,692 -48,936 -16,170,256 -16,056,956 -12,934,270
Free Cash Flow -10,179,409 -11,744,338 -10,882,988